Home>>Signaling Pathways>> Microbiology & Virology>> HSV>>Ganciclovir

Ganciclovir (Synonyms: BW 759, 2'Nor2'deoxyguanosine)

Catalog No.GC11331

Antiviral drug for CMV infections

Products are for research use only. Not for human use. We do not sell to patients.

Ganciclovir Chemical Structure

Cas No.: 82410-32-0

Size Price Stock Qty
10mM (in 1mL DMSO)
$45.00
In stock
50mg
$34.00
In stock
250mg
$135.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Ganciclovir (DHPG) is a potent antiviral drug used to treatment of cytomegalovirus (CMV) infections [1].

Ganciclovir (DHPG) is a nucleoside analogue and has shown the activity against viral thymidine kinase (tk) in the Herpesviridae family, including human cytomegalovirus and herpes simplex virus types I and II as well as Epstein-Barr virus. In addition, Ganciclovir has been reported to inhibit the proliferation of uninfected cells, most significantly of bone marrow cells, because of the function of inhibiting viral replication. Apart from these, Ganciclovir has been revealed to reduce the activation of microglial in wild-type C57BL/6 mice and inhibit proliferation of microglial in wild-type FvB mice [1].

References:
[1] Ding Z1, Mathur V, Ho PP, James ML, Lucin KM, Hoehne A, Alabsi H, Gambhir SS, Steinman L, Luo J, Wyss-Coray T. Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation. J Exp Med. 2014 Feb 10; 211(2):189-98.

Reviews

Review for Ganciclovir

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ganciclovir

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.